FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

vvasimigtori,	D.O.	20040	

STATEME	NT C	F CH	ANG

ES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-0287									
Estimated average burden									
hours per response: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  GARCIA PETER S  (Last) (First) (Middle)  C/O ALX ONCOLOGY HOLDINGS INC.				AI AI 3. [	Issuer Name and Ticker or Trading Symbol     ALX ONCOLOGY HOLDINGS INC [     ALXO ]  3. Date of Earliest Transaction (Month/Day/Year)     08/23/2021							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  X Officer (give title below) Chief Financial Officer				
866 MALCOLM ROAD, SUITE 100						f Amendment, Date	e of Orig	inal Fi	iled (Month/Da		6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BURLINGAME CA 94010									X	<b>,</b>						
(City)	(S	tate)	(Zip)										1 613011			
		Tab	le I - I	Non-Deriv	ative	e Securities A	cquir	ed, D	isposed o	f, or B	enefic	ially (	Owned			
Date			2. Transacti Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		ransaction Disposed Of (D) (Instr. 3, 4 and ode (Instr.				Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
							Code	v	Amount	(A) or (D)	Price		Reported Transact (Instr. 3 a	ion(s)		(Instr. 4)
Common Stock			08/23/20	)21		М		60,000	Α	\$4.	08	69,331		D		
Common Stock		08/23/20	)21		S <sup>(1)</sup>		1,593	D	\$70.8	551 <sup>(2)</sup>	1 <sup>(2)</sup> 67,738		D			
Common Stock		08/23/20	)21		S <sup>(1)</sup>		3,497	D	\$72.03	349 <sup>(3)</sup>	64,	241	D			
Common Stock			08/23/20	)21		S <sup>(1)</sup>		18,060	D	\$72.60	607(4)	46,	181	D		
Common	Stock			08/23/20	)21		S <sup>(1)</sup>		4,008	D	\$73.5	707(5)	42,	173	D	
Common	Stock			08/23/2	)21		S <sup>(1)</sup>		19,448	D	\$75.0	863(6)	22,	725	D	
Common	Stock			08/23/20	)21		S <sup>(1)</sup>		10,743	D	\$75.70	067(7)	11,	982	D	
Common Stock			08/23/20	)21	1			2,616	D	\$76.60	628 <sup>(8)</sup> 9,366		366	D		
Common Stock 08/23/20			)21		s <sup>(1)</sup> 35 D \$77.5609 <sup>(9)</sup> 9,331		331	D								
		٦	Table I			Securities Ac calls, warran							wned			
1. Title of 2. 3. Transaction 3A. Deemed 4. Derivative Conversion Date Execution Date, Tr					Transa Code (I		Expir (Mon	te Exer ation I th/Day		of Secu	ing ive Secur	De Se	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		7. Title and of Security Underlying Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Ownership Form:	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$4.08	08/23/2021		М			40,630	(10)	03/09/2030	Common Stock	40,630	\$0.00	95,659	D		
Employee Stock Option (right to buy)	\$4.08	08/23/2021		М			19,370	(11)	03/09/2030	Common Stock	19,370	\$0.00	80,468	D		

## **Explanation of Responses:**

- $1. \ The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 14, 2021.$
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$70.27 to \$71.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (9) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$71.27 to \$72.265, inclusive.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$72.275 to \$73.265, inclusive.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$73.30 to \$74.295, inclusive.
- $6. \ The price reported in Column \ 4 \ is \ a weighted average price. These shares were sold in multiple transactions at prices ranging from \$74.31 \ to \$75.305, inclusive.$
- 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$75.31 to \$76.295, inclusive.
- 8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$76.31 to \$77.27, inclusive.
- 9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$77.46 to \$77.79, inclusive.
- 10. The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vested on January 2, 2021 and 1/36th of the remaining shares vest monthly
- 11. The option is subject to an early exercise provision and is immediately exercisable. One-fourth of the shares subject to the option vest on March 9, 2021 and 1/36th of the remaining shares vest monthly

## Remarks:

/s/ Peter Garcia

08/24/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.